Nyrada (ASX:NYR) Other Stockholders Equity: A$-0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NYR Nyrada Inc ASX:NYR
33 GF Score
Price A$0.50
! 1 Warning Sign
View Full Analysis

What is Nyrada Other Stockholders Equity?

Nyrada ASX:NYR -13.04% 33 Other Stockholders Equity is A$-0.00 Mil as of Dec. 2025. GuruFocus rates ASX:NYR with a GF Score™ of 33/100. The stock has 1 warning sign investors should review.

Nyrada's Other Stockholders Equity for the quarter that ended in Dec. 2025 was A$-0.00 Mil.

Nyrada's quarterly Other Stockholders Equity declined from Dec. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil) and declined from Jun. 2025 (A$0.00 Mil) to Dec. 2025 (A$-0.00 Mil).

Nyrada's annual Other Stockholders Equity increased from Jun. 2023 (A$-0.00 Mil) to Jun. 2024 (A$0.00 Mil) and increased from Jun. 2024 (A$0.00 Mil) to Jun. 2025 (A$0.00 Mil).

Nyrada Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Nyrada's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nyrada Other Stockholders Equity Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Stockholders Equity
Get a 7-Day Free Trial 0.00 0.00 -0.00 0.00 0.00

Nyrada Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 -0.00
ASX:NYR
33GF Score
Nyrada Inc ASX:NYR
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nyrada Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of A$-0.00 Mil mean?
Nyrada (ASX:NYR) has a Other Stockholders Equity of A$-0.00 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Nyrada and its competitors.
Is Nyrada's Other Stockholders Equity too high?
Nyrada's current Other Stockholders Equity is A$-0.00 Mil. Overall, Nyrada has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Nyrada's Other Stockholders Equity compare to VRTX and REGN?
Nyrada's Other Stockholders Equity of A$-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Nyrada and its competitors. Nyrada's current Other Stockholders Equity is A$-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nyrada stock overvalued right now?
Nyrada (ASX:NYR) has a current Other Stockholders Equity of A$-0.00 Mil. The current Other Stockholders Equity is A$-0.00 Mil. Nyrada's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Nyrada (ASX:NYR), the current Other Stockholders Equity is A$-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nyrada Business Description

Address 180 George Street, Sydney Place, Level 22/23, Salesforce Tower, Sydney, NSW, AUS, 2000
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. It operates in one segment: research and development of drugs focusing on small molecules with potential therapeutic benefit in areas of medical needs. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.
33GF Score

Get the complete analysis for ASX:NYR

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.50
Price